Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + BDB001 + radiotherapy
- Development stage
- Unknown
- Lead developer
- Seven and Eight Biopharmaceuticals
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, External Beam Radiation
01
Overview
Atezolizumab + BDB001 + radiotherapy is an investigational combination therapy being studied for the treatment of advanced solid tumors, including pancreatic adenocarcinoma. Atezolizumab is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors to enhance antitumor immune responses. BDB001 is a first-in-class Toll-like receptor 7/8 (TLR7/8) agonist designed to stimulate innate immunity and promote antitumor activity by activating dendritic cells and other immune cells. Radiotherapy (specifically stereotactic body radiation therapy, SBRT) is used to induce immunogenic cell death and further enhance the immune response against tumors. The combination aims to synergistically boost both innate and adaptive immunity for improved cancer control[1][2][3][4][7].
- Brand names
- Tecentriq
- Other names
- Atezolizumab + BDB001 + RTAtezolizumab + BDB001 + SBRTAtezolizumab + BDB001 + Radiotherapy
02
Targets
TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + BDB001 + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + BDB001 + radiotherapy.